Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients and prospectively select participants based on PTGR1 overexpression and DNA-damage-repair deficiency.
The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies, addressing a significant unmet need in bladder cancer treatment. This development further advances Lantern's AI-driven precision oncology strategy through its proprietary RADR platform, which uses machine learning to identify patient populations most likely to benefit from its drug candidates.
LP-184 is an acylfulvene derivative that targets DNA damage repair pathways, and its efficacy is enhanced in tumors with PTGR1 overexpression and DNA repair deficiencies. The EMA clearance marks a key regulatory milestone for Lantern, enabling the company to expand its clinical footprint into Europe. The trial is expected to generate data that could support broader development of LP-184 across multiple cancer types.
In addition to bladder cancer, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. The company's pipeline also includes LP-284, a TC-NER targeting compound in hematologic and solid tumors, and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma.
Lantern's AI capabilities extend beyond drug development through its RADR platform, which is now commercially available as a subscription-based research tool for the global biomedical community. The company also operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The EMA clearance for LP-184 in bladder cancer underscores the potential of AI-guided precision oncology to deliver targeted therapies to patients with high unmet needs. As Lantern continues to advance its pipeline, the outcomes of this trial could provide critical insights into the role of biomarker selection in improving treatment outcomes for advanced cancers.
